Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DyNAMIc adaptive versus continuous encorafenib + binimetinib in advanced BRAF-mutant cutaneous melanoma
ISRCTN14643179Phase 2Recruiting
- Sponsor
- The Christie
- Start
- Nov 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of encorafenib and binimetinib in cutaneous melanoma (CM) (2 arms), sponsored by The Christie. Started Nov 2024; status: recruiting.
02
Drugs
encorafenibbinimetinib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on ISRCTN14643179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14643179.